TY - JOUR
T1 - Distal technologies and type 1 diabetes management
AU - Duke, Danny C.
AU - Barry, Samantha
AU - Wagner, David V.
AU - Speight, Jane
AU - Choudhary, Pratik
AU - Harris, Michael A.
N1 - Funding Information:
PC has received personal fees and travel support and participated in advisory boards for Medtronic, Roche Diabetes Care, Abbott Diabetes Care, Dexcom, and Ascenscia, outside this work. JS reports that her institution (the Australian Centre for Behavioural Research in Diabetes) received non-financial support, speaker fees, honoraria (advisory board), and travel support from Roche Diabetes Care (Australia); speaker fees and travel support from AstraZeneca and Roche Diabetes Care (global); grants, non-financial support, honoraria (consultancy and advisory board), and travel support from Sanofi; grants and honoraria (consultancy) from Abbott Diabetes Care; speaker fees from J&J Diabetes Institute and Novo Nordisk; non-financial support, speaker fees, and travel support from Medtronic; and honoraria (advisory board) and travel support from Janssen, outside this work. DCD, SB, DVW, and MAH declare no competing interests.
Funding Information:
Acknowledgments We received no substantial financial support for this work that could have influenced its outcome. We thank Natalie Koskela, whose tireless assistance made the manuscript possible.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/2
Y1 - 2018/2
N2 - Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.
AB - Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.
UR - http://www.scopus.com/inward/record.url?scp=85028588394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028588394&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(17)30260-7
DO - 10.1016/S2213-8587(17)30260-7
M3 - Review article
C2 - 28867311
AN - SCOPUS:85028588394
SN - 2213-8587
VL - 6
SP - 143
EP - 156
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 2
ER -